155 related articles for article (PubMed ID: 38016985)
1. Ovarian recurrence risk assessment using machine learning, clinical information, and serum protein levels to predict survival in high grade ovarian cancer.
Mysona DP; Purohit S; Richardson KP; Suhner J; Brzezinska B; Rungruang B; Hopkins D; Bearden G; Higgins R; Johnson M; Bin Satter K; McIndoe R; Ghamande S
Sci Rep; 2023 Nov; 13(1):20933. PubMed ID: 38016985
[TBL] [Abstract][Full Text] [Related]
2. High-Grade Serous Ovarian Cancer: Use of Machine Learning to Predict Abdominopelvic Recurrence on CT on the Basis of Serial Cancer Antigen 125 Levels.
Shinagare AB; Balthazar P; Ip IK; Lacson R; Liu J; Ramaiya N; Khorasani R
J Am Coll Radiol; 2018 Aug; 15(8):1133-1138. PubMed ID: 29789232
[TBL] [Abstract][Full Text] [Related]
3. The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients-results from the OVCAD study.
Nassir M; Guan J; Luketina H; Siepmann T; Rohr I; Richter R; Castillo-Tong DC; Zeillinger R; Vergote I; Van Nieuwenhuysen E; Concin N; Marth C; Hall C; Mahner S; Woelber L; Sehouli J; Braicu EI
Tumour Biol; 2016 Mar; 37(3):3009-16. PubMed ID: 26419591
[TBL] [Abstract][Full Text] [Related]
4. The clinical outcome of epithelial ovarian cancer patients with apparently isolated lymph node recurrence: a multicenter retrospective Italian study.
Gadducci A; Cosio S; Zola P; Sostegni B; Ferrero AM; Teti G; Cristofani R; Sartori E
Gynecol Oncol; 2010 Mar; 116(3):358-63. PubMed ID: 19954826
[TBL] [Abstract][Full Text] [Related]
5. High grade, advanced, serous ovarian cancer with low serum CA125 levels.
Asali A; Haj-Yehia N; Zehavi T; Perry T; Beiner M; Fishman A; Kadan Y
J Obstet Gynaecol; 2021 Oct; 41(7):1107-1111. PubMed ID: 33427544
[TBL] [Abstract][Full Text] [Related]
6. Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study.
Bagnoli M; Canevari S; Califano D; Losito S; Maio MD; Raspagliesi F; Carcangiu ML; Toffoli G; Cecchin E; Sorio R; Canzonieri V; Russo D; Scognamiglio G; Chiappetta G; Baldassarre G; Lorusso D; Scambia G; Zannoni GF; Savarese A; Carosi M; Scollo P; Breda E; Murgia V; Perrone F; Pignata S; De Cecco L; Mezzanzanica D;
Lancet Oncol; 2016 Aug; 17(8):1137-1146. PubMed ID: 27402147
[TBL] [Abstract][Full Text] [Related]
7. Survival after recurrence in early-stage high-risk epithelial ovarian cancer: a Gynecologic Oncology Group study.
Chan JK; Tian C; Teoh D; Monk BJ; Herzog T; Kapp DS; Bell J
Gynecol Oncol; 2010 Mar; 116(3):307-11. PubMed ID: 19944452
[TBL] [Abstract][Full Text] [Related]
8. Factors related to recurrence after pathological complete response to postoperative chemotherapy in patients with epithelial ovarian cancer.
Karagol H; Saip P; Eralp Y; Topuz S; Berkman S; Ilhan R; Topuz E
Tumori; 2009; 95(2):207-11. PubMed ID: 19579867
[TBL] [Abstract][Full Text] [Related]
9. [Diagnostic and prognostic value of tumor markers, scores (clinical and biological) algorithms, in front of an ovarian mass suspected of an epithelial ovarian cancer: Article drafted from the French Guidelines in oncology entitled "Initial management of patients with epithelial ovarian cancer" developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY under the aegis of CNGOF and endorsed by INCa].
Bendifallah S; Body G; Daraï E; Ouldamer L
Gynecol Obstet Fertil Senol; 2019 Feb; 47(2):134-154. PubMed ID: 30733191
[TBL] [Abstract][Full Text] [Related]
10. Serum CA125 level as predictors of the efficacy of olaparib maintenance therapy for platinum-sensitive relapsed ovarian cancer.
Asano F; Momomura M; Morisada T; Tsushima K; Haruna Y; Shibuya H; Matsumoto H; Kobayashi Y
J Obstet Gynaecol Res; 2023 Dec; 49(12):2883-2888. PubMed ID: 37735981
[TBL] [Abstract][Full Text] [Related]
11. A combined score of clinical factors and serum proteins can predict time to recurrence in high grade serous ovarian cancer.
Mysona D; Pyrzak A; Purohit S; Zhi W; Sharma A; Tran L; Tran P; Bai S; Rungruang B; Ghamande S; She JX
Gynecol Oncol; 2019 Mar; 152(3):574-580. PubMed ID: 30578005
[TBL] [Abstract][Full Text] [Related]
12. External validation of a 'response score' after neoadjuvant chemotherapy in patients with high-grade serous ovarian carcinoma with complete clinical response.
Zorzato PC; Zannoni GF; Tudisco R; Pasciuto T; Di Giorgio A; Franchi M; Scambia G; Fagotti A
Int J Gynecol Cancer; 2020 Jan; 30(1):67-73. PubMed ID: 31754067
[TBL] [Abstract][Full Text] [Related]
13. The effect of complete surgical staging and adjuvant chemotherapy on survival in stage I, grade 1 and 2 endometrioid ovarian carcinoma.
Swift BE; Covens A; Mintsopoulos V; Parra-Herran C; Bernardini MQ; Nofech-Mozes S; Hogen L
Int J Gynecol Cancer; 2022 Apr; 32(4):525-531. PubMed ID: 34969829
[TBL] [Abstract][Full Text] [Related]
14. Expression profile of COL2A1 and the pseudogene SLC6A10P predicts tumor recurrence in high-grade serous ovarian cancer.
Ganapathi MK; Jones WD; Sehouli J; Michener CM; Braicu IE; Norris EJ; Biscotti CV; Vaziri SA; Ganapathi RN
Int J Cancer; 2016 Feb; 138(3):679-88. PubMed ID: 26311224
[TBL] [Abstract][Full Text] [Related]
15. Establishment and verification of the nomogram that predicts the 3-year recurrence risk of epithelial ovarian carcinoma.
Hu J; Jiao X; Zhu L; Guo H; Wu Y
BMC Cancer; 2020 Sep; 20(1):938. PubMed ID: 32993522
[TBL] [Abstract][Full Text] [Related]
16. [Recurrence risk factors of platinum-sensitive epithelial ovarian cancer].
Yan XJ; Liang LZ; Zeng ZY; Liu JH; Yuan SH; Wei M
Ai Zheng; 2005 Jun; 24(6):751-4. PubMed ID: 15946495
[TBL] [Abstract][Full Text] [Related]
17. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.
Tattersall A; Ryan N; Wiggans AJ; Rogozińska E; Morrison J
Cochrane Database Syst Rev; 2022 Feb; 2(2):CD007929. PubMed ID: 35170751
[TBL] [Abstract][Full Text] [Related]
18. Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial.
Shi T; Zhu J; Feng Y; Tu D; Zhang Y; Zhang P; Jia H; Huang X; Cai Y; Yin S; Jiang R; Tian W; Gao W; Liu J; Yang H; Cheng X; Zang R
Lancet Oncol; 2021 Apr; 22(4):439-449. PubMed ID: 33705695
[TBL] [Abstract][Full Text] [Related]
19. HOXA4/HOXB3 gene expression signature as a biomarker of recurrence in patients with high-grade serous ovarian cancer following primary cytoreductive surgery and first-line adjuvant chemotherapy.
Miller KR; Patel JN; Zhang Q; Norris EJ; Symanowski J; Michener C; Sehouli J; Braicu I; Destephanis DD; Sutker AP; Jones W; Livasy CA; Biscotti C; Ganapathi RN; Tait DL; Ganapathi MK
Gynecol Oncol; 2018 Apr; 149(1):155-162. PubMed ID: 29402501
[TBL] [Abstract][Full Text] [Related]
20. The prognostic factor for recurrence in advanced-stage high-grade serous ovarian cancer after complete clinical remission: a nested case-control study.
Wang Q; Zheng Y; Wang P; Zhang J; Liu H; Li Q; Yin R; Bian C; Peng H; Peng Z
J Ovarian Res; 2021 Dec; 14(1):179. PubMed ID: 34930386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
